Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer: A Potential Strategy for Systemic Therapy Deferral
Stephanie O. Dudzinski(The University of Texas MD Anderson Cancer Center), Matthew S. Ning(The University of Texas MD Anderson Cancer Center), Joe Y. Chang(The University of Texas MD Anderson Cancer Center), Mark Zafereo(Texas Medical Center), James Welsh(The University of Texas MD Anderson Cancer Center), G. Brandon Gunn(The University of Texas MD Anderson Cancer Center), Ethan B. Ludmir(The University of Texas MD Anderson Cancer Center), Vicente Rodrigues Marczyk(The University of Texas MD Anderson Cancer Center), Steven G. Waguespack(The University of Texas MD Anderson Cancer Center), Aileen B. Chen(Dana-Farber Cancer Institute), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Anita K. Ying(The University of Texas MD Anderson Cancer Center), Steven H. Lin(The University of Texas MD Anderson Cancer Center), Jay P. Reddy(The University of Texas MD Anderson Cancer Center), Thomas H. Beckham(Medical University of South Carolina), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Steven I. Sherman(Johns Hopkins University), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Zhongxing Liao(The University of Texas MD Anderson Cancer Center), Anna Lee(The University of Texas MD Anderson Cancer Center), Michael S. O’Reilly(The University of Texas MD Anderson Cancer Center), Quynh-Nhu Nguyen(The University of Texas MD Anderson Cancer Center), Saumil Gandhi(The University of Texas MD Anderson Cancer Center), Jack Phan(The University of Texas MD Anderson Cancer Center), Chenyang Wang(The University of Texas MD Anderson Cancer Center), Sarah Hamidi(The University of Texas MD Anderson Cancer Center)
Cited by 5
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766